Shinichi Sasaki 研究室

主宰者：Shinichi Sasaki

順天堂大学

AI 要約（直近 5 年の研究成果）

要約はまだ生成されていません。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（40 件）

[2025] Development and evaluation of a mobile application for comprehensive and personalized asthma self-management support
DOI: https://doi.org/10.1183/13993003.congress-2025.pa2880
[2025] Tracheal meandering may predict prognosis in idiopathic pleuroparenchymal fibroelastosis: a retrospective observational study
DOI: https://doi.org/10.1038/s41598-025-25721-x
[2024] Squamous cell carcinoma of the bronchus associated with human papillomavirus infection
DOI: https://doi.org/10.1016/j.rmcr.2024.102162
[2024] Atypical Adult-Onset IgA Vasculitis With Extremely Rare Complications Including Diffuse Alveolar Hemorrhage, Heart Failure, and Stroke
DOI: https://doi.org/10.7759/cureus.75607
[2024] Combination effect of Mepolizumab and Endobronchial Watanabe Spigot (<scp>EWS)</scp> in drug‐induced eosinophilic pneumonia complicated by refractory pneumothorax
DOI: https://doi.org/10.1002/rcr2.70021
[2024] Tear fluid cytokine analysis: a non-invasive approach for assessing retinopathy of prematurity severity
DOI: https://doi.org/10.1007/s10384-024-01084-0
[2023] Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
DOI: https://doi.org/10.1007/s10147-023-02414-x
[2023] Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.8576
[2023] Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy
DOI: https://doi.org/10.1016/j.jtho.2023.09.1446
[2023] Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting
DOI: https://doi.org/10.1155/2023/3302405

続きを表示（残り 30 件）

[2023] A biomarker study of atezolizumab (atezo) + bevacizumab (bev) + carboplatin (carbo) + paclitaxel (pac) (ABCP) for patients with NSCLC harboring EGFR mutations (EGFRm) after failure of TKI therapy: NEJ043.
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9079
[2023] Association of IL-4 with pachychoroid neovasculopathy
DOI: https://doi.org/10.1038/s41598-023-28108-y
[2023] Infection control measures based on drug susceptibility to Acinetobacter baumannii
DOI: https://doi.org/10.1002/ams2.855
[2023] A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
DOI: https://doi.org/10.1016/j.ejca.2023.113469
[2023] MO1-2 Subgroup analysis of atezo + bev + carbo + pac for previously treated patients with EGFRm NSCLC (NEJ043)
DOI: https://doi.org/10.1016/j.annonc.2023.09.148
[2023] EP11.03-04 Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC
DOI: https://doi.org/10.1016/j.jtho.2023.09.1176
[2022] Antiviral cytotoxic T lymphocyte responses for long term prognosis of corneal infection by cytomegalovirus in immunocompetent subjects
DOI: https://doi.org/10.1038/s41598-022-09312-8
[2022] Histopathologic Features of Immune-related Adverse Events in the Gastrointestinal Tract: A Case of Severe Acute Respiratory Syndrome Coronavirus 2 and Cytomegalovirus Infection in a Patient with Lung Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors
DOI: https://doi.org/10.14789/jmj.jmj22-0004-cr
[2022] 国産能動型宇宙放射線線量計の開発状況と将来展望
[2022] NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.9110
[2022] Multiple Types of Taste Disorders among Patients with COVID-19
DOI: https://doi.org/10.2169/internalmedicine.9065-21
[2022] Difference in Clinical Features and Prognosis of Patients Diagnosed with Idiopathic Pleuroparenchymal Fibroelastosis by Subtype Using New Japanese Clinical Diagnostic Criteria
DOI: https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2727
[2022] Mycobacterium avium-intracellulare complex promote release of pro-inflammatory enzymes matrix metalloproteinases by inducing neutrophil extracellular trap formation
DOI: https://doi.org/10.1038/s41598-022-09017-y
[2022] A Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer
DOI: https://doi.org/10.1159/000526977
[2021] Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting
DOI: https://doi.org/10.2147/dddt.s284819
[2021] P16‐63: Efficacy of high‐ versus low‐dose corticosteroid therapy in patients with acute exacerbation of idiopathic interstitial pneumonia: A nationwide observational study
DOI: https://doi.org/10.1111/resp.14150_972
[2021] O25‐4: A real‐world study of the safety and efficacy of low‐dose nintedanib for idiopathic pulmonary fibrosis
DOI: https://doi.org/10.1111/resp.14149_149
[2021] Determination of probability of causative pathogen in infectious keratitis using deep learning algorithm of slit-lamp images
DOI: https://doi.org/10.1038/s41598-021-02138-w
[2021] P16‐60: Post COVID‐19 organizing pneumonia treated with mycophenolate mofetil
DOI: https://doi.org/10.1111/resp.14150_969
[2021] P16‐61: Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain
DOI: https://doi.org/10.1111/resp.14150_970
[2021] P7‐46: Airflow obstruction on spirometry in patients undergoing surgery using general anesthesia
DOI: https://doi.org/10.1111/resp.14150_489
[2021] P16‐85: Differences in the therapeutic effects of corticosteroid and immunosuppressants between the two subtypes of systemic sclerosis‐associated interstitial lung disease
DOI: https://doi.org/10.1111/resp.14150_994
[2021] O25‐5: The end of the road for patients with interstitial lung disease, are we doing enough?
DOI: https://doi.org/10.1111/resp.14149_150
[2021] [A Case of Malignant Lymphoma of the Ileum and Uterine Cervix with Perforating Peritonitis of Ileum Tumor Detected during Chemotherapy].
[2021] CT Guided Needle Biopsy of Peripheral Lesions–Lesion Characteristics That May Increase the Diagnostic Yield and Reduce the Complication Rate
DOI: https://doi.org/10.3390/jcm10092031
[2021] Prognostic Factors in Acute Exacerbation of Chronic Fibrosing Interstitial Pneumonia; A Multicenter Prospective Study and Preliminary Analysis
DOI: https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1870
[2021] Prognostic Factor for Idiopathic Interstitial Pneumonias Patients with Pneumothorax Complication: A Multicenter Retrospective Study
DOI: https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1871
[2021] 宇宙放射線線量計測器PS-TEPC の長期運用のための取り組み
[2021] Zinc‐finger E‐box‐binding homeobox 1 <scp>(ZEB1)</scp> plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib
DOI: https://doi.org/10.1111/1759-7714.13937
[2021] P7‐44: Involvement of airway hyperresponsiveness in the therapy for COPD
DOI: https://doi.org/10.1111/resp.14150_487

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（40 件）

科研費（0 件）

所属学会・役職（0 件）